FOLFOX


Also found in: Acronyms, Wikipedia.

FOLFOX

Oxaliplatin, leucovorin, and fluorouracil, chemotherapeutic drugs used to treat cancers of the intestine, pancreas, and stomach, among other organs.
References in periodicals archive ?
In Study 3, the most commonly reported adverse reactions ([greater than or equal to] 20%) in patients with wild-type KRAS mCRC receiving Vectibix (6 mg/kg every two weeks) and FOLFOX therapy (N = 322) were diarrhea, stomatitis, mucosal inflammation, asthenia, paronychia, anorexia, hypomagnesemia, hypokalemia, rash, acneiform dermatitis, pruritus, and dry skin.
And while FOLFOX is a systemic treatment, DEBIRI is a
Many of these questions, however, will be answered by CALGB/SWOG 80405, a very important study [7-9] designed to assess the optimal combination of biologic agents for first-line treatment of metastatic colorectal cancer, and a head-to-head of cetuximab versus bevacizumab with doctors prescribing FOLFOX or FOLFIRI.
In a small randomized phase II multicenter study of cetuximab plus FOLFOX or cetuximab plus FOLFIRI in the neo-adjuvant treatment of nonresectable colorectal liver metastases confined to the liver (the CELIM study), response rates of 85% and 66% were reported in the FOLFOX6 and FOLFIRI arms, respectively [48].
In several other studies, oxaliplatin as part of a combination regimen known as FOLFOX, which also includes fluorouracil and leucovorin, was consistently associated with a doubling of the rate of patients whose tumors shrunk by at least 50%, compared with any single drug.
Further, the annual cost of therapy was also driven by the increased adoption of combination therapies such as FOLFOX (5-fluorouracil, leucovorin and oxaliplatin), FOLFIRI (5-fluorouracil, leucovorin and irinotecan), 5FU/LV (5-fluorouracil, leucovorin) and CAPOX (capecitabine and oxaliplatin) in the first-line and second-line treatment of metastatic colorectal cancer patients.
Vectibix is now approved in the European Union (EU) for the treatment of adult patients with WT RAS mCRC: in first-line in combination with FOLFOX or FOLFIRI; in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan); and as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Many cancer patients who receive chemotherapy, in particular 5-fluorouracil (5-FU)-based regimens such as FOLFOX and FOLFIRI, suffer from severe diarrhea induced by damage to their intestines caused by the chemotherapy.
Patients will be randomised either to the regimen of FOLFOX +
In the adjuvant setting, patients with stage III colon cancer (tumor-node-metastasis T1-3, N1-2 [any lymph node involvement], M0) should receive oxaliplatin with 5-fluorouracil (5-FU) and leucovorin (the FOLFOX regimen); or capecitabine (Xeloda); or 5-FU and leucovorin without oxaliplatin, Paul Engstrom, M.